President Trump’s nominee to head the Food and Drug Administration has received millions of dollars in payments from about 20 health care companies he worked with in the private sector, according to his federal disclosure forms, which include a plan to recuse himself for a year from any agency decisions involving those firms if he is confirmed by the Senate.
The nominee, Dr. Scott Gottlieb, has done a range of work for companies, among them large drug makers like GlaxoSmithKline and Bristol-Myers Squibb, including consulting, public speaking and even acting as chief executive officer in the case of a small start-up. Dr. Gottlieb also has relationships with a host of other small companies he invested in as a venture partner at New Enterprise Associates as well as at T.R. Winston & Co., a bank that is focused on health care investments.
Dr. Gottlieb’s financial relationships with these companies are sure to revive debate over whether someone with such close ties to the industry should be put in charge of an agency that controls its fate: Several consumer groups and others have already criticized his nomination. The issue is also likely to come up in his confirmation hearings in the Senate.